By A Mystery Man Writer
The Triple Negative Breast Cancer (TNBC) subtype is known to have a more aggressive clinical course compared to other breast cancer subtypes. Targeted therapies for this type of breast cancer are limited and patients are mostly treated with conventional chemo- and radio-therapies which are not specific and do not target resistant cells. Therefore, one of the major clinical challenges is to find compounds that target the drug-resistant cell populations which are responsible for reforming secondary tumours. The molecular profiling of the different TNBC subtypes holds a promise for better defining these resistant cells specific to each tumour. To this end, a better understanding of TNBC heterogeneity and cancer stemness is required, and extensive genomic analysis can help to understand the disease complexity and distinguish new molecular drivers that can be targeted in the clinics. The use of persister cancer cell-targeting therapies combined with other therapies may provide a big advance to improve TNBC patients’ survival.
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries - Sung - 2021 - CA: A Cancer Journal for Clinicians - Wiley Online Library
Cancers, Free Full-Text
Free Books, Magazines & Care Journals for Cancer Patients
Cancers, Free Full-Text
Cancers, Free Full-Text, sonic sprites modgen
Cancer: Overview, causes, treatments, and types
Cancers, Free Full-Text, jack smith ferreiro
Cancer Today
Does Sugar Actually Feed Cancer? - The New York Times
Remission, cancer-free, no evidence of disease: What's the difference?
All Cancers on Wooden Scrabble Tiles · Free Stock Photo
Cancers, Free Full-Text
Cancers, Free Full-Text, clube aurora ao vivo
Cancers, Free Full-Text, sonic sprites modgen
Cancers, Free Full-Text, papa's burgeria apk